Skip to content

BillionToOne, Inc. BLLN Common Stock Shares Outstanding

Common Stock Shares Outstanding at other companies

Tango Therapeutics logo
Tango TherapeuticsTNGX
$313.61M
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
$121.56M
Guardant Health logo
Guardant HealthGH
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX

Other financials

Income statement

See full
Revenue$108.4M+83.8%
Gross profit$79.1M+108%
Operating income$17.8M+870%
Net income$18.0M+551%
EPS (diluted)$0.34+187%

Balance sheet

See full
Cash & equivalents$537.5M+181%
Total debt$144.2M
Total equity$505.6M+300%
Total assets$700.7M

Cash flow

See full
Operating cash flow$15.4M+488%
CapEx$4.5M+90.5%
Free cash flow$11.0M+3,842%

Valuation

See full
Market cap$4.84B

Profitability

See full
Gross margin70.4%
Operating margin-96.9%
Net margin8.4%
FCF margin-83.4%

Returns & leverage

See full
Debt / equity0.3×
Current ratio10.9×

Where this comes from

Reported directly by BillionToOne, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue.

The official record: BillionToOne, Inc. ’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BillionToOne, Inc. 's common stock shares outstanding.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BillionToOne, Inc. 's common stock shares outstanding?
BillionToOne, Inc. (BLLN) reported common stock shares outstanding of $614.21M in Q1 2026.
What does common stock shares outstanding mean?
This represents the total number of common shares held by all shareholders, including institutional investors and insiders. It serves as the denominator for calculating earnings per share and is a key indicator of potential equity dilution. Changes in this figure reflect share repurchases, new issuances, or conversion of convertible securities.